This observation is consistent with the possibility that, in a subset of patients, MS pathophysiology may be driven predominantly by TNF-mediated innate immune mechanisms that are not adequately targeted by anti-CD20 therapy, as implicated in the pivotal immunopathological studies [47]. Here, TNF is linked to myeloid sarcoma.